AIM2 and hepatocellular carcinoma: Notably, the deficiency of AIM2 appears to ameliorate the activation of the inflammasome, a critical component of innate immune responses, thereby mitigating liver inflammation and the proliferative responses that are integral to the initiation phase of HCC (114).